JNJyoji Nakagawara

Jyoji Nakagawara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jyoji Nakagawara has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Etsuro Mori

    From Nakamura Memorial Hospital (J.N.), Hokkaido, Japan; National Cerebral and Cardiovascular Center (K.M.), Osaka, Japan; National Hospital Organization Kyushu Medical Center (Y.O.), Fukuoka, Japan; Saitama Medical University International Medical Center (N.T.), Saitama, Japan; University of Tokushima Graduate School (S.N.), Tokushima, Japan; Tohoku University Graduate School of Medicine (E.M.), Miyagi, Japan; Federation of National Public Service Personnel Mutual Aid Associations Tachikawa...

    1 shared publication
  • Hidekazu Takada

    Departments of Neurosurgery and Stroke Center, Nakamura Memorial Hospital

    1 shared publication
  • Hirohiko Nakamura

    Departments of Neurosurgery and Stroke Center, Nakamura Memorial Hospital

    1 shared publication
  • Hironori Sugio

    Departments of Neurosurgery and Stroke Center, Nakamura Memorial Hospital

    1 shared publication
  • J Nakamura

    Department of Neurosurgery, Nakamura Memorial Hospital, South-1, West-14, Chuo-ku, Sapporo 060, Japan

    1 shared publication
  • K Suematsu

    Department of Neurosurgery, Nakamura Memorial Hospital, South-1, West-14, Chuo-ku, Sapporo 060, Japan

    1 shared publication

Latest Publications

  • Open Access

    Diagnostic Imaging of Higher Brain Dysfunction in Patients With Adult Moyamoya Disease Using Statistical Imaging Analysis for [123I]Iomazenil Single Photon Emission Computed Tomography

    by Jyoji Nakagawara, Toshiaki Osato, Kenji Kamiyama, Kaori Honjo, Hironori Sugio, Kentarou Fumoto, Takeo Murahashi, Hidekazu Takada, Toshiichi Watanabe, Hirohiko Nakamura

    [123I]iomazenil (IMZ) is a specific radioligand for the central benzodiazepine (BZ) receptor that may be useful as a marker of cortical neuron loss after cerebral ischemia using single photon emission computed tomography (SPECT). This study used statistical imaging analysis for IMZ-SPECT to investigate the relationship between higher brain dysfunction and cortical neuron loss in the medial frontal lobes, to establish a confirmatory diagnosis of higher brain dysfunction in patients with adult moyamoya disease. IMZ-SPECT was estimated by three-dimensional stereotactic surface projections (3D-SSP). Cortical neuron loss was analyzed using the stereotactic extraction estimation (SEE) method (level 3: gyrus level) for 3D-SSP Z-score maps (Z-score >2). Extent of pixels with significant reduction of BZ receptor density within the target gyri (i.e. bilateral medial frontal gyri [MFGs] and anterior cingulate gyri [ACGs]) was calculated. In 6 patients with higher brain dysfunction, significant cortical neuron loss was observed in the bilateral MFGs in 4 patients, unilateral MFG in 1 patient, and bilateral ACGs in 2 patients. In 12 patients without higher brain dysfunction, no significant cortical neuron loss was observed in the bilateral MFGs or ACGs, and mild loss was observed in the bilateral MFGs in 2 patients, unilateral MFG in 4 patients, and unilateral ACG in 2 patients. Long-standing mild hemodynamic ischemia in the anterior circulation of patients with adult moyamoya disease could lead to incomplete brain infarction within the medial frontal lobes. Statistical imaging analysis using 3D-SSP and SEE methods for IMZ-SPECT could demonstrate significant cortical neuron loss in the bilateral frontal medial cortices involving MFG and/or ACG which correlate with higher brain dysfunction in patients with adult moyamoya disease.


  • Thrombolysis With 0.6 mg/kg Intravenous Alteplase for Acute Ischemic Stroke in Routine Clinical Practice

    by Jyoji Nakagawara, Kazuo Minematsu, Yasushi Okada, Norio Tanahashi, Shinji Nagahiro, Etsuro Mori, Yukito Shinohara, Takenori Yamaguchi, for J-MARS Investigators

    Background and Purpose— In Japan, alteplase at 0.6 mg/kg was approved in October 2005 for use within 3 hours of stroke onset by the Ministry of Health, Labor and Welfare (MHLW). The aim of the Japan post-Marketing Alteplase Registration Study (J-MARS), which was requested by MHLW at the time of approval, was to assess the safety and efficacy of 0.6 mg/kg alteplase in routine clinical practice for the Japanese. Methods— A total of 7492 patients from 942 centers were enrolled in the J-MARS, an open-label, nonrandomized, observational study, from October 2005 to October 2007. Primary outcome measures were symptomatic intracranial hemorrhage (a deterioration in NIHSS score ≥4 from baseline) and favorable outcome (modified Rankin Scale score, 0–1) at 3 months after stroke onset. Results— The proportion of patients with symptomatic intracranial hemorrhage in 7492 patients (safety analysis) was 3.5% (95% confidence interval [CI], 3.1%–3.9%) within 36 hours and 4.4% (95% CI, 3.9%–4.9%) at 3 months. The overall mortality rate was 13.1% (95% CI, 12.4%–13.9%) and the proportion of patients with fatal symptomatic intracranial hemorrhage was 0.9% (95% CI, 0.7%–1.2%). The outcomes at 3 months were available for 4944 patients and the proportion of favorable outcome (efficacy analysis) was 33.1% (95% CI, 31.8%–34.4%). The subgroup analysis in patients between 18 and 80 years with a baseline NIHSS score Conclusions— These data suggest that 0.6 mg/kg intravenous alteplase within 3 hours of stroke onset could be safe and effective in routine clinical practice for the Japanese.